Monte Rosa Therapeutics I...

NASDAQ: GLUE · Real-Time Price · USD
4.36
-0.08 (-1.80%)
At close: Aug 14, 2025, 3:59 PM
4.27
-2.06%
After-hours: Aug 14, 2025, 04:26 PM EDT

Monte Rosa Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
75.62M n/a n/a n/a
Cost of Revenue
8.12M 6.22M 8.56M 2.13M
Gross Profit
67.5M -6.22M -8.56M -2.13M
Operating Income
-81.11M -143.31M -112.38M -72.88M
Interest Income
10.57M 9.33M 3.76M 46K
Pretax Income
-70.13M -135.01M -108.5M -73.96M
Net Income
-72.7M -135.35M -108.5M -73.96M
Selling & General & Admin
35.17M 32.04M 27.32M 15.73M
Research & Development
121.56M 105.05M 85.06M 57.16M
Other Expenses
-8.12M n/a n/a n/a
Operating Expenses
148.61M 137.09M 112.38M 72.88M
Interest Expense
n/a n/a 3.76M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
156.73M 143.31M 112.38M 72.88M
Income Tax Expense
2.57M 338K n/a n/a
Shares Outstanding (Basic)
73.91M 51.4M 47.23M 46.54M
Shares Outstanding (Diluted)
73.91M 51.4M 47.23M 46.54M
EPS (Basic)
-0.98 -2.63 -2.3 -1.59
EPS (Diluted)
-0.98 -2.63 -2.3 -1.59
EBITDA
-72.99M -137.09M -108.64M -70.75M
EBIT
-81.11M -143.31M -108.5M -73.96M
Depreciation & Amortization
8.12M 6.22M 3.75M 2.13M